U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH NIH News National Heart, Lung, and Blood Institute (NHLBI) <https://www.nhlbi.nih.gov>
For Immediate Release: Thursday, August 25, 2022 CONTACT: NHLBI Engagement and Media Relations Branch, 301-496-5449, <e-mail:nhlbi_news@xxxxxxxxxxxxx> NOVEL BLOOD TEST HELPS EVALUATE SEVERITY IN PULMONARY ARTERIAL HYPERTENSION, A RARE LUNG DISEASE Researchers at the National Institutes of Health have found that a novel blood test can be used to easily evaluate disease severity in patients with pulmonary arterial hypertension (PAH) and predict survivability. PAH is a rare, life-threatening
condition that causes unexplained high blood pressure in the lungs. In early clinical studies, the researchers showed the test to significantly improve upon conventional tests, some of which use invasive tools. The new blood test measures DNA fragments shed by damaged cells. Researchers found that these fragments, called cell-free DNA, were elevated in the blood of patients with PAH and increase with disease severity. If future studies confirm
the findings, this first-of-its-kind blood test for PAH patients could allow doctors to intervene faster to prevent or delay progression of the disease and possibly save lives. Cell-free DNA is a relatively new analytical technique that is growing in its potential
medical uses, which include the early detection of heart- and lung-transplant rejection as well as early detection of cancer.
The study was funded by the National Heart, Lung, and Blood Institute (NHLBI) and the NIH Clinical Center, both part of NIH. The findings will appear online in the journal Circulation, a publication of the American Heart Association. PAH is a rare form of pulmonary hypertension that can cause difficulty breathing, chest pain, and fatigue. The disease, whose exact cause is unknown, is estimated to affect less than 50,000 people in the United States, according to the
NIH’s Genetic and Rare Diseases Information Center <https://rarediseases.info.nih.gov/diseases/7501/pulmonary-arterial-hypertension>. It is characterized by progressive narrowing and blockage of the small pulmonary arteries of the lungs, strain on the right
side of the heart, and eventual death from heart failure < https://www.nhlbi.nih.gov/health/heart-failure>. The damage to the lung in severe cases can require lung transplantation. Patients with PAH have a high death rate, and the condition mostly affects
women. Despite treatment advances, it currently has no cure. Current tests used to monitor PAH severity rely on established risk prediction scores based on clinical symptoms and on the use of an invasive catheter to measure pressure in the lungs. Doctors sometimes use echocardiography, or heart imaging,
to measure pressures in the heart as an indirect measurement of lung pressure, but these tests tend to lack reliability and sensitivity.
“Researchers have been actively searching for novel, less-invasive approaches to evaluate PAH severity, disease progression, and response to therapy for more than a decade. These cell-free DNA analyses represent progress toward that goal,”
said study co-author Michael A. Solomon, M.D., M.B.A., who is part of the NHLBI Cardiovascular Branch and co-director of the NIH Clinical Center Pulmonary Arterial Hypertension Section. Sean Agbor-Enoh, M.D., Ph.D., study co-author and chief of the NHLBI’s Laboratory of Applied Precision Omics, agreed. “Here we’re proposing a one-time test where you collect a vial of blood from a patient and use that to predict survival.
We’re very encouraged by the early results.” In the current study, the research team analyzed cell-free DNA from blood samples taken from 209 adult patients, predominately women, diagnosed with PAH at two large U.S. medical centers. The researchers compared the results to cell-free
DNA measured from a control group of 48 healthy volunteers without PAH at the NIH Clinical Center.
They found that cell-free DNA was elevated in patients with PAH, and also found that cell-free DNA concentrations increased in proportion to the severity of the disease. Patients with the highest level of cell-free DNA had a 3.8 times greater
risk of either death or a need for lung transplantation compared to those with the lowest level of cell-free DNA, the researchers said.
Further analyses of cell-free DNA samples revealed that multiple tissue types – including the heart, blood vessels, fat tissue, and inflammatory cells circulating in the blood – were affected by PAH. The new blood test will allow researchers
to better pinpoint the specific tissues involved in the PAH disease process. This knowledge may lead to new drug interventions for PAH, whose current treatment options may slow but not halt or reverse disease progression.
In addition to funding from the Intramural Research Program of the NHLBI, this research is supported by the NIH Clinical Center Research Award for Staff Clinicians Program, the NIH Distinguished Scholar Award, the Lasker Clinical Research
Scholars Program, and the Intramural Research Programs of the NIH Clinical Center.
About the National Heart, Lung, and Blood Institute (NHLBI): NHLBI is the global leader in conducting and supporting research in heart, lung, and blood diseases and sleep disorders that advances scientific knowledge, improves public health,
and saves lives. For more information, visit <www.nhlbi.nih.gov>. About the NIH Clinical Center: The NIH Clinical Center is the world’s largest hospital entirely devoted to clinical research. It is a national resource that makes it possible to rapidly translate scientific observations and laboratory discoveries
into new approaches for diagnosing, treating, and preventing disease. Over 1,600 clinical research studies are conducted at the NIH Clinical Center, including those focused on cancer, infectious diseases, blood disorders, heart disease, lung disease, alcoholism
and drug abuse. For more information about the Clinical Center, visit: <https://www.cc.nih.gov/> . About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting
and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit <https://www.nih.gov>. NIH...Turning Discovery into Health -- Registered, U.S. Patent and Trademark Office --- STUDY: Plasma Cell-free DNA Predicts Survival and Maps Specific Sources of Injury in Pulmonary Arterial Hypertension. Circulation. DOI: 10.1161/CIRCULATIONAHA.121.056719 ### This NIH News Release is available online at: <https://www.nih.gov/news-events/news-releases/novel-blood-test-helps-evaluate-severity-pulmonary-arterial-hypertension-rare-lung-disease> To subscribe (or unsubscribe) from NIH News Release mailings, go to <http://service.govdelivery.com/service/subscribe.html?code=USNIH_1>. If you subscribed via the NIH LISTSERV, go to <https://list.nih.gov/cgi-bin/wa.exe?A0=nihpress>. |